Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Cleverly

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|February 14, 2008
TGF-beta signalling-related markers in cancer patients with bone metastasisJose Baselga, Mace L Rothenberg, Josep Tabernero, et al.
British Journal of Cancer|October 16, 2018
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancerDavide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, et al.
Investigational New Drugs|December 23, 2014
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancerJordi Rodón, Michael Carducci, Juan M Sepulveda-Sánchez, et al.
Cancer Chemotherapy and Pharmacology|March 20, 2019
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancerDavide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, et al.
Neuro-Oncology|February 24, 2016
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastomaAlba A Brandes, Antoine F Carpentier, Santosh Kesari, et al.
International Journal of Molecular Sciences|May 9, 2017
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and LomustineDavid Capper, Andreas von Deimling, Alba A Brandes, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|February 14, 2008
TGF-beta signalling-related markers in cancer patients with bone metastasisJose Baselga, Mace L Rothenberg, Josep Tabernero, et al.
British Journal of Cancer|October 16, 2018
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancerDavide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, et al.
Investigational New Drugs|December 23, 2014
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancerJordi Rodón, Michael Carducci, Juan M Sepulveda-Sánchez, et al.
Cancer Chemotherapy and Pharmacology|March 20, 2019
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancerDavide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, et al.
Neuro-Oncology|February 24, 2016
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastomaAlba A Brandes, Antoine F Carpentier, Santosh Kesari, et al.
International Journal of Molecular Sciences|May 9, 2017
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and LomustineDavid Capper, Andreas von Deimling, Alba A Brandes, et al.
Pageof 2